BioSpace News Archive

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Portola Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc.

Aquestive Therapeutics, Inc., a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, reported financial results for the first quarter ended March 31, 2020 and provided an update on recent developments in its business.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced its financial results for the first quarter ended March 31, 2020.

First Quarter 2020 Total Revenue grew 68% to $8.7M and Product Sales grew 78% to $8.2M over Q1 2019

AB680, the first small-molecule CD73 inhibitor in the clinic, continues in a Phase 1 dose-escalation combination trial for first-line treatment of pancreatic cancer, with a recommended dose for expansion anticipated to be established in mid-2020

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the first quarter ended April 5, 2020.

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended March 31, 2020.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced that it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler and Canaccord Genuity (collectively “Agents”).

Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced financial results for its fiscal third-quarter 2020 and provided an update on recent business activity.

Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr for the treatment of complicated urinary tract infection and acute pyelonephritis.